Pneumococcal vaccine study for children with sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a single dose of a new pneumococcal vaccine (21-valent) in children and teens with sickle cell disease. It aims to see if the vaccine can help protect against serious infections caused by pneumococcus bacteria, which are especially dangerous for people with SCD.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 17 years old.
- You must have a doctor's diagnosis of sickle cell disease.
- If you are a female who can have children, you must not be pregnant or breastfeeding and agree to use birth control.
- You cannot have received the 20-valent pneumococcal conjugate vaccine before.
- You cannot have a weak immune system, a history of certain infections, or a serious neurological disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if the measles vaccine works well in children with sickle cell disease. It aims to help protect children with this condition from measles.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This trial tests a catch-up pneumococcal vaccine for children and adolescents who may have missed some doses. It aims to see how safe and effective the vaccine is in healthy kids aged 15 months to 17 years.
This study tests a new vaccine to protect infants from pneumococcal disease (a serious bacterial infection). Researchers want to see how well the vaccine works and how safe it is in healthy babies aged 2–6 months.
This trial tests a new pneumococcal vaccine (PCV24) in healthy infants and children. It aims to protect against serious infections like pneumonia and meningitis caused by pneumococcal bacteria.
This trial tests a 13-valent pneumococcal conjugate vaccine to prevent pneumonia and serious infections caused by pneumococcus bacteria. It may be a good option if your child has never had a pneumococcal vaccine before.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.